• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Refractory anti-NMDAR encephalitis with multiple nosocomial infections: optimizing the therapeutical options.难治性抗 NMDAR 脑炎伴多次院内感染:优化治疗选择。
Neurodegener Dis Manag. 2024;14(3-4):63-67. doi: 10.1080/17582024.2024.2388508. Epub 2024 Aug 19.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Successful Early Treatment of Anti-N-Methyl-d-Aspartate Receptor Encephalitis Associated With Small Cell Lung Cancer in an Elderly Male Patient: A Case Report.老年男性小细胞肺癌相关抗N-甲基-D-天冬氨酸受体脑炎的成功早期治疗:一例报告
Neuropsychopharmacol Rep. 2025 Sep;45(3):e70044. doi: 10.1002/npr2.70044.
4
Anti-NMDAR encephalitis triggered by EBV and HSV-1: A case report and literature review.由EB病毒和单纯疱疹病毒1型引发的抗N-甲基-D-天冬氨酸受体脑炎:一例报告及文献综述
Medicine (Baltimore). 2025 Jul 11;104(28):e43338. doi: 10.1097/MD.0000000000043338.
5
Neuroleptic intolerance in the context of anti-N-methyl-D-aspartate receptor encephalitis: A systematic review and synthesis of global case reports.抗 N-甲基-D-天冬氨酸受体脑炎背景下的神经阻滞剂不耐受:全球病例报告的系统评价和综合分析。
Acta Neurol Scand. 2022 Nov;146(5):410-428. doi: 10.1111/ane.13693. Epub 2022 Sep 9.
6
Refractory "status dyskineticus" in a child with post-herpes simplex virus 1 N-methyl-D-aspartate receptor encephalitis: a case report.1型单纯疱疹病毒感染后N-甲基-D-天冬氨酸受体脑炎患儿的难治性“运动障碍状态”:病例报告
BMC Neurol. 2025 Aug 29;25(1):368. doi: 10.1186/s12883-025-04346-7.
7
Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study.奥法木单抗治疗抗N-甲基-D-天冬氨酸受体自身免疫性脑炎(OFF-AE)的疗效与安全性:一项前瞻性、多中心队列研究
Ann Neurol. 2025 Feb 24. doi: 10.1002/ana.27218.
8
Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis: A systematic review of reported cases.抗N-甲基-D-天冬氨酸受体脑炎患者的临床特征、治疗方法及预后:已报道病例的系统评价
Epilepsy Behav. 2017 Mar;68:57-65. doi: 10.1016/j.yebeh.2016.12.019. Epub 2017 Jan 19.
9
Alternative treatment in adolescent with anti-NMDA receptor encephalitis catatonia.青少年抗N-甲基-D-天冬氨酸受体脑炎所致紧张症的替代治疗
Neurocase. 2024 Dec;30(6):234-237. doi: 10.1080/13554794.2024.2436214. Epub 2024 Dec 4.
10
Exploring the neuroprotective role of artesunate in mouse models of anti-NMDAR encephalitis: insights from molecular mechanisms and transmission electron microscopy.探讨青蒿琥酯在抗 NMDAR 脑炎小鼠模型中的神经保护作用:来自分子机制和透射电子显微镜的见解。
Cell Commun Signal. 2024 May 14;22(1):269. doi: 10.1186/s12964-024-01652-4.

本文引用的文献

1
Immunotherapy for Refractory Autoimmune Encephalitis.免疫疗法治疗难治性自身免疫性脑炎。
Front Immunol. 2021 Dec 16;12:790962. doi: 10.3389/fimmu.2021.790962. eCollection 2021.
2
Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management.自身免疫性脑炎:诊断和急性治疗的最佳实践建议。
J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):757-768. doi: 10.1136/jnnp-2020-325300. Epub 2021 Mar 1.
3
Is Antimicrobial Treatment Effective During Therapeutic Plasma Exchange? Investigating the Role of Possible Interactions.治疗性血浆置换期间抗菌治疗是否有效?探究可能的相互作用的作用。
Pharmaceutics. 2020 Apr 25;12(5):395. doi: 10.3390/pharmaceutics12050395.
4
Early Bortezomib Therapy for Refractory Anti-NMDA Receptor Encephalitis.硼替佐米早期治疗难治性抗N-甲基-D-天冬氨酸受体脑炎
Front Neurol. 2020 Mar 27;11:188. doi: 10.3389/fneur.2020.00188. eCollection 2020.
5
Treatment strategies for autoimmune encephalitis.自身免疫性脑炎的治疗策略。
Ther Adv Neurol Disord. 2017 Aug 16;11:1756285617722347. doi: 10.1177/1756285617722347. eCollection 2018.
6
[The risk of epileptic seizures during antibiotic therapy].[抗生素治疗期间癫痫发作的风险]
Wiad Lek. 2017;70(4):820-826.
7
Risk factors for mortality in patients with anti-NMDA receptor encephalitis.抗N-甲基-D-天冬氨酸受体脑炎患者的死亡危险因素。
Acta Neurol Scand. 2017 Oct;136(4):298-304. doi: 10.1111/ane.12723. Epub 2016 Dec 27.
8
Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.抗 NMDAR 脑炎患者的临床经验和实验室研究。
Lancet Neurol. 2011 Jan;10(1):63-74. doi: 10.1016/S1474-4422(10)70253-2.
9
Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab.无肿瘤的抗N-甲基-D-天冬氨酸受体脑炎对包括利妥昔单抗在内的免疫疗法的反应
Neurology. 2008 Dec 2;71(23):1921-3. doi: 10.1212/01.wnl.0000336648.43562.59.

难治性抗 NMDAR 脑炎伴多次院内感染:优化治疗选择。

Refractory anti-NMDAR encephalitis with multiple nosocomial infections: optimizing the therapeutical options.

机构信息

Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, 682041, India.

Department of Neurology, Amrita Institute of Medical Science & Research Centre, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, 682041, India.

出版信息

Neurodegener Dis Manag. 2024;14(3-4):63-67. doi: 10.1080/17582024.2024.2388508. Epub 2024 Aug 19.

DOI:10.1080/17582024.2024.2388508
PMID:39155818
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11457615/
Abstract

Nosocomial infections during immunotherapy pose a dilemma in the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, where a lack of consensus guidelines for this rare disease marks a significant gap in the existing knowledge. This case reports about an 18-year-old female diagnosed with anti-NMDAR encephalitis who was found to be refractory to first- and second-line treatment. During her hospital stay, the patient encountered nearly six episodes of infection, which delayed the use of next-line intervention. It was observed that switching over to the next line of treatment during infections may produce sub-therapeutic outcomes. Thereby, the case highlights the need for de-escalation and appropriate selection of immunosuppression therapy during nosocomial infections and how monotherapy with the patient-tolerated first-line agent can be appropriate during infection.

摘要

免疫治疗期间的医院感染给抗 N-甲基-D-天冬氨酸受体(NMDAR)脑炎的治疗带来了困境,这种罕见疾病缺乏共识指南,这是现有知识中的一个重大空白。本病例报告介绍了一位 18 岁女性,被诊断为抗 NMDAR 脑炎,对一线和二线治疗均无反应。在住院期间,患者遭遇了近六次感染,这延迟了二线干预的使用。观察到在感染期间转换至下一线治疗可能产生低于治疗效果。因此,该病例强调了在医院感染期间需要降级和适当选择免疫抑制治疗,以及在感染期间使用患者耐受的一线药物单药治疗可能是合适的。